NGC Update Service: November 7, 2011

-----Original Message-----
From: Agency for Healthcare Research and Quality (AHRQ)
Sent: 11/7/2011 5:03:20 PM
To: guyperea@live.com
Subject: NGC Update Service: November 7, 2011

November 7, 2011 New This Week Guideline Synthesis Chronic Obstructive Pulmonary Disease: Diagnosis and Management of Stable COPD Update: includes revised recommendations from ACP and GOLD. Guideline Summaries American College of Physicians Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. This updates a previously published guideline summary. Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: a clinical practice guideline from the American College of Physicians. Cincinnati Children's Hospital Medical Center Best evidence statement (BESt). Axillary temperature taking tools: the evidence for change. Best evidence statement (BESt). Best care environment for adolescent patients with eating disorders. Best evidence statement (BESt). Oral anxiolytic medication prior to ambulatory healthcare encounters for individuals with special developmental and behavioral challenges. Best evidence statement (BESt). Screening of hypertension in pediatric patients with diabetes. Best evidence statement (BESt). Use of Lactobacillus rhamnosus GG in children with acute gastroenteritis. Evidence-based care guideline for management of idiopathic toe walking in children and young adults ages 2 through 21 years. European Society of Cardiology Guidelines for the diagnosis and management of syncope (version 2009). This updates a previously published guideline summary. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009). This updates a previously published guideline summary. Management of acute myocardial infarction in patients presenting with ST-segment elevation. This updates a previously published guideline summary. Announcements Coming Soon NGC and NQMC Will Each Launch a New Survey! It's your chance to be heard so make sure you respond to both! Please tell us what we're doing right. More importantly, tell us what we could improve. We are listening. Let us hear from you. Health Awareness Topics - November 2011 American Diabetes Month (see related guidelines and the guideline synthesis page for various diabetes-related topics) COPD Awareness Month (see related guidelines and the guideline synthesis page for various COPD-related topics) Lung Cancer Awareness Month (see related guidelines) Pancreatic Cancer Awareness Month (see related guidelines) NGC Spotlight New evidence report added! Visit the AHRQ Evidence Reports page for a listing of reports produced under AHRQ's Evidence-based Practice Program and Effective Health Care Program. U.S. Food and Drug Administration (FDA) Advisories November 4, 2011: Tumor Necrosis Factor (TNF) blockers, Azathioprine and/or Mercaptopurine: Healthcare professionals should remain vigilant for cases of malignancy in patients treated with TNF blockers, and report such cases to MedWatch. FDA continues to receive reports of a rare cancer of white blood cells (known as Hepatosplenic T-Cell Lymphoma or HSTCL, primarily in adolescents and young adults being treated for Crohn's disease and ulcerative colitis with TNF blockers, as well as with azathioprine, and/or mercaptopurine. October 25, 2011: Xigris [drotrecogin alfa (activated)] Market Withdrawal: FDA notified healthcare professionals and the public that Eli Lilly and Company announced a worldwide voluntary market withdrawal of Xigris [drotrecogin alfa (activated)]. In a recently completed clinical trial (PROWESS-SHOCK trial), Xigris failed to show a survival benefit for patients with severe sepsis and septic shock. Xigris treatment should not be started in new patients. Xigris treatment should be stopped in patients being treated with Xigris. All remaining Xigris product should be returned to the supplier from whom it was purchased. October 21, 2011: Methylene Blue: FDA updated healthcare professionals and the public on the potential drug interaction between methylene blue and serotonergic psychiatric medications. Most cases from the FDA's Adverse Event Reporting System (AERS) of serotonin syndrome in patients given serotonergic psychiatric medications and methylene blue occurred in the context of parathyroid surgery, which involved the intravenous administration of methylene blue as a visualizing agent. Methylene blue doses ranged from 1 mg/kg to 8 mg/kg. October 21, 2011: Zyvox (linezolid): The FDA updated information on the potential drug interaction between linezolid and serotonergic psychiatric medications. Not all serotonergic psychiatric drugs have an equal capacity to cause serotonin syndrome with linezolid. Most cases from the FDA's Adverse Event Reporting System (AERS) of serotonin syndrome with linezolid occurred in patients taking specific serotonergic psychiatric drugs, namely a selective serotonin reuptake inhibitor (SSRI) or a serotonin norepinephrine reuptake inhibitor (SNRI). It is unclear at this time whether linezolid administration in patients receiving other psychiatric drugs with lesser degrees of serotonergic activity poses a comparable risk. NGC's Sister Resources Find Innovations and QualityTools classified by disease or clinical category, patient population, setting of care, stage of care, and more in AHRQ's Health Care Innovations Exchange Web site. Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC). Update your subscriptions, modify your password or E-mail address, or stop subscriptions at any time on your Subscriber Preferences Page If you have any questions or problems with the subscription service, E-mail: updates@subscriptions.ahrq.gov. For other inquiries, Contact Us. If you have questions about AHRQ's activities, please try to find the answers by checking our Home Page, where we have established links to various topical areas. Also check the News & Information section and Frequently Asked Questions. You may also Search or Browse the Web Site. These features are designed to assist you in obtaining the information you are seeking. This service is provided to you at no charge by the Agency for Healthcare Research and Quality (AHRQ). This email was sent to guyperea@live.com using GovDelivery, on behalf of: Agency for Healthcare Research and Quality (AHRQ) · 540 Gaither Road · Rockville, MD 20850 · 301-427-1364